ArticleBMC infectious diseases2015
Human papillomavirus prevalence in South African women and men according to age and human immunodeficiency virus status.
Article in BMC infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- Pooled it
- HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer.AIDS (London, England) · 2018Pooled it
- The use of Web-based interactive technology to promote HPV vaccine uptake among young females: a randomized controlled trial.BMC women's health · 2021Trial
- Trial
- Prevalence and genotype distribution of human papillomavirus (HPV) among adolescent girls and young women in a high HIV burden rural area of South Africa: a cross-sectional survey.Research square · 2026Article
- Race-specific temporal trends of HPV-related cancers in South Africa: An analysis of the South African National Cancer Registry, 2011-2022.International journal of cancer · 2026Article
- Population impact of South Africa's human papillomavirus (HPV) vaccination programme on HPV prevalence in adolescent girls with and without HIV: a repeat cross-sectional study.The Lancet. Global health · 2026Article
- Prevalence and factors associated with high-risk human papillomavirus infection and cervical lesions among women with HIV in Addis Ababa, Ethiopia.BMC cancer · 2025Article
- Article
- APTIMA mRNA vs. DNA-Based HPV Assays: Analytical Performance Insights from a Resource-Limited South African Setting.International journal of molecular sciences · 2025Article
- Feasibility of First-Void Urinary and Vaginal Self-Sampling for High-Risk Human Papillomavirus Testing Among Women Living With Human Immunodeficiency Virus in Guinea-Bissau-A Multicenter Cross-Sectional Study.Journal of medical virology · 2025Article
- Prevalence of Human Papillomavirus and Genotype Correlation with Cervical Lesions at the University Teaching Hospital of Kigali.The American journal of tropical medicine and hygiene · 2025Article
- High burden of human papillomavirus and premalignant cervical lesions among women starting HIV treatment in KwaZulu-Natal, South Africa.Sexually transmitted infections · 2025Article
- First Report of HPV Genotyping and Distribution in People Living with and Without HIV from Iran and the Middle East.Current HIV research · 2025Article
- Article
- Impact of single-dose HPV vaccination on HPV 16 and 18 prevalence in South African adolescent girls with and without HIV.Journal of the National Cancer Institute. Monographs · 2024Article
- Identification of HPV16 Lineages in South African and Mozambican Women with Normal and Abnormal Cervical Cytology.Viruses · 2024Article
- A population based study on human papillomavirus infection and associated risk factors among women of the remote South Andaman Island, India.BMC women's health · 2024Article
- Role of the epithelium in human papillomavirus and human immunodeficiency virus infections in the female genital tract.Frontiers in reproductive health · 2024Review
- Analysis of multi-site HPV infection and vaccination willingness among men who have sex with men in Tianjin, China.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBoth cervical cancer and human immunodeficiency virus (HIV) are major public health problems in Sub-Saharan Africa. The objectives of the study were to investigate human papillomavirus (HPV) prevalence according to age, HIV status and gender.
methodsParticipants were 208 HIV-negative women, 278 HIV-positive women, 325 HIV-negative men and 161 HIV-positive men between the ages of 18-66 years. HPV types were determined in cervical and penile cells by Roche Linear Array HPV genotyping assay.
resultsHPV prevalence was 36.7 % (76/207; 95 % confidence intervals (CI): 30.4-43.4 %) in HIV-negative women, with the highest prevalence of 61.0 % (25/41; 95 % CI: 45.7-74.4 %) in women aged 18-25 years. HPV prevalence was 74.0 % (205/277; 95 % CI: 68.5-78.8 %) in HIV-positive women, with the highest prevalence of 86.4 % (38/44; 95 % CI: 72.9-94.0 %) in women aged 18-25 years. HPV prevalence was found to decrease with increasing age in HIV-negative women (P = 0.0007), but not in HIV-positive women (P = 0.898). HPV prevalence was 50.8 % (159/313; 95 % CI: 45.3-56.3 %) in HIV-negative men, with the highest prevalence of 77.0 % (27/35; 95 % CI: 60.7-88.2 %) in men aged 18-25 years. HPV prevalence was 76.6 % (121/158; 95 % CI: 69.2-82.9 %) in HIV-positive men, with the highest prevalence of 87.5 % (7/8; 95 % CI: 50.8-99.9 %) in men 18-25 years of age. HPV prevalence was found to decrease with increasing age in HIV-negative men (P = 0.004), but not in HIV-positive men (P = 0.385). HIV-positive women had a significantly higher prevalence of one or more HPV type(s) in the bivalent (HPV-16/18: 20 % 55/277, 9 % 12/207; P <0.001), quadrivalent (HPV-6/11/16/18: 26 % 71/277, 12 % 24/207; P = 0.001) and nonavalent vaccine (HPV-6/11/16/18/31/33/52/56/58: 65 % 181/277, 24 % 50/207; P <0.001) compared to HIV-negative women. Similar observation were observed in men for bivalent (20 % 32/158, 10 % 30/313; P = 0.001), quadrivalent (35 % 56/158, 13 % 41/313; P <0.001) and nonavalent vaccine (75 % 119/158, 28 % 87/313; P <0.001).
conclusionsThis study demonstrated high HPV prevalence among HIV-positive women and men in all age groups. The high prevalence of HPV types found in bivalent, quadrivalent and nonavalent vaccines in South African HIV-positive and HIV-negative women and men demonstrate that this population will greatly benefit from current HPV vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.